Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
UNIVERCELLS logo — company profile

UNIVERCELLS

Founded 2013 Belgium Belgium 24 employees Series D Total: $235.17M Biotechnology, Health Care +1

General Information

Company Name UNIVERCELLS
Founded Year 2013
Location Belgium Belgium
Founders / Decision Makers
Team member
Employees 24
Industries Biotechnology, Health Care, Manufacturing
Funding Stage Series D
Business Model B2B, Platform, B2G
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with UNIVERCELLS. To contact UNIVERCELLS, visit univercells.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does UNIVERCELLS compare?

A PDF of UNIVERCELLS and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting UNIVERCELLS soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About UNIVERCELLS

UNIVERCELLS, founded in 2013 and headquartered in Belgium, is a biotech company that seeks to revolutionize the way vaccines and therapeutics are designed and produced by leveraging innovative technological platforms. Operating within the Biotechnology, Health Care, and Manufacturing industries, the company embodies a spirit of continuous evolution and adaptation.

The company’s innovative approach enables them to offer transformative solutions to the pharmaceutical and biotech industries, driven by not only scientific expertise but also an entrepreneurial mindset. Leveraging their unique bioprocess knowledge, UNIVERCELLS stands out as a key player driving substantial change in the sector.

In their latest funding round on 19 October 2022, the company secured a €44.00M Series D investment, drawing backing from prominent investors such as Adjuvant Capital, Belgian Federal Investment, Global Health Investment Corporation, among others. This investment underscores confidence in UNIVERCELLS’ capability to deliver impactful solutions in healthcare innovation.

Business keywords: biologics, bioproduction, vaccines, viral vectors, technology transfer, RNA platform, regulatory affairs, clinical testing, pharmaceutical industry, CDMO, bioproduction training, GMP production facilities, healthcare value chain

Services & Products

Development of transformative biotech platforms
Acceleration of drug development for pharma and biotech
Facilitation of biotech drug availability worldwide
Technology transfer and implementation
Collaborative projects in RNA-based therapies

Target Customers

Biotech Companies Pharmaceutical Companies Drug Developers Healthcare Institutions Governments seeking to develop a local biotech industry

Funding Rounds & Investors (12)

View All
Funding Stage Amount Investors Lead Investors Date
Series D €44.00M 8
Adjuvant Capital Belgian Federal Investment Global Health Investment Corporation
Adjuvant Capital, Belgian Federal Investment +6
19 Oct 2022
Series C €70.00M 1
HTH VC
HTH VC
11 Feb 2021
Series C €20.00M 7
Korea Investment Partners Adjuvant Capital Belgian Federal Investment
Korea Investment Partners, Adjuvant Capital +5
17 Dec 2020
Series C Undisclosed 1
TCD Capital (ex TheClubDeal)
TCD Capital (ex TheClubDeal)
31 Aug 2020
Venture Round €50.00M 1
Kohlberg Kravis Roberts
18 Feb 2020
Grant $14.30M 1
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation
13 Jun 2019
Series B €16.00M 6
Korea Investment Partners the Innovation Fund TCD Capital (ex TheClubDeal)
Korea Investment Partners, the Innovation Fund +4
16 Jul 2018
Grant €2.40M 1
Walloon
Walloon
23 Jan 2018
Series A €3.00M -
15 Dec 2017
Grant $12.00M 1
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation
16 Dec 2016

View All 12 Funding Rounds

UNIVERCELLS Alternatives & Competitors

View All Alternatives
UNIVERCELLS vs
Paratus Sciences
Paratus Sciences United States

Translating evolutionary insights into first-in-class medicines

Series A
19 employees
Biotechnology, Health Care
UNIVERCELLS vs
IDT Biologika
IDT Biologika Germany

Your full-service CDMO for viral vaccines, cell & gene therapeutics and other biologics protecting h...

502 employees
Health Care, Manufacturing
UNIVERCELLS vs
Galena Pharma Oy
Galena Pharma Oy Finland

Big in expertise, agile in action

Private Equity
32 employees
Biotechnology, Logistics
View all alternatives

FAQ About UNIVERCELLS

For humanity to thrive, we need transformative thinking in how vaccines and therapeutics are designed and produced. At Univercells, we believe in the power of small adaptations to drive big change. We embrace the spirit of evolution in everything we do. We are biotech innovators. We are scientist...
UNIVERCELLS was founded in 2013.
UNIVERCELLS is headquartered in Belgium.
UNIVERCELLS operates in Biotechnology, Health Care and Manufacturing. Its work centres on biologics, bioproduction, vaccines and viral vectors. Its customers include Biotech Companies, Pharmaceutical Companies and Drug Developers.
UNIVERCELLS has a B2B, Platform and B2G business model. Its revenue comes from Licensing, Product Sales and Service Fee.
UNIVERCELLS has approximately 24 employees.
UNIVERCELLS has completed 12 funding rounds, raising a total of $235.17M. The latest funding stage is Series D.
UNIVERCELLS offers: Development of transformative biotech platforms, Acceleration of drug development for pharma and biotech, Facilitation of biotech drug availability worldwide, Technology transfer and implementation, Collaborative projects in RNA-based therapies.
Top alternatives and competitors to UNIVERCELLS include Paratus Sciences, IDT Biologika, Galena Pharma Oy, Antiverse, KABS Laboratories Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
UNIVERCELLS and Paratus Sciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for UNIVERCELLS, https://bouncewatch.com/company/univercells, updated 11 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes